AstraZeneca
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Past deals in Nebraska
Matthew Walker Comprehensive Health Center
Grant in 2014
Matthew Walker Comprehensive Health Center, Inc. provides healthcare and health education services. It provides pediatric care, family and internal medicine, general dentistry, ophthalmology, geriatrics, obstetrics and gynecology, nutrition, mental health, pharmacy, radiology, and diagnostic laboratory testing and screening services. The company was founded in 1968 and is based in Nashville, Tennessee.
Ashland-Boyd County Health Department
Grant in 2014
Ashland-Boyd County Health Department is located in the Appalachian highlands of eastern Kentucky where the state lines of Kentucky, Ohio and West Virginia meet. Our mission, “To improve the quality of life for all who live, work and play in Boyd County through disease prevention, health promotion, environmental safety and public health preparedness,” is rooted in our long and proud history of serving the residents of our small, yet vibrant community.
ZS Pharma, Inc.
Acquisition in 2015
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions.
The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.
ADC Therapeutics SA
Series E in 2019
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Acerta Pharma, LLC
Acquisition in 2015
Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.
ADC Therapeutics SA
Series C in 2015
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Medopad
Corporate Round in 2022
Huma is a global health tech company with a mission to help people with chronic, complex, and rare diseases to live longer, better lives.
Huma works with world-leading healthcare providers, pharmaceutical, insurance and technology companies, including Apple and Tencent, to build a connected digital health ecosystem. Headquartered in London, Medopad has offices in the US and China.
Cullgen
Series C in 2023
Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on selective degradation of disease-causing proteins, novel treatment for cancer, inflammatory and autoimmune diseases, including targets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases.
PhaseBio Pharmaceuticals
Series C in 2015
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Almirall
Acquisition in 2014
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. The company researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
MdBio Foundation
Grant in 2014
MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere.
MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards.
Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.
The Health Wagon
Grant in 2014
The Health Wagon is a nonprofit 501(c)(3) organization providing mobile health services to the medically underserved in southwest Virginia since 1980. The Health Wagon’s mission is to provide compassionate, quality healthcare to the medically underserved in the mountains of Appalachia. The Health Wagon visits 10 sites in six counties – Buchanan, Dickenson, Lee, Russell, Scott and Wise counties – to serve a severely medically underserved population. The Health Wagon currently has two mobile health units and two stationary clinics servicing southwest Virginia.
Allegiance Health Foundation
Grant in 2014
Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan. We combine hospital-based care with a full range of services for all members of our community. Allegiance is a leader in forming community partnerships which innovatively address wellness and preventative needs. We are proudly entering our 10th decade of serving the people of south central Michigan with local, high-quality care.Comprised of more than 40 different facilities, Allegiance reaches the residents of Jackson, Hillsdale, Lenawee, Ingham, Calhoun and Washtenaw counties and beyond. Wherever we are in the region, our mission remains constant. We lead our community to better health and well-being at every stage of life. Our vision is to create Michigan’s healthiest community through exceptional health care and inspiring a passion for wellness.
Viela Bio
Series A in 2018
Viela Bio is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Omthera Pharmaceuticals
Acquisition in 2013
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.
ethris GmbH
Corporate Round in 2017
ethris GmbH develops therapeutic solutions for diseases with unmet medical need. It offers Magnetovax, a platform for personalized tumor vaccines that are localized and activated in tumors by magnetic fields. The company also offers SNIM RNA, a biopharmaceutical platform for therapies of rare diseases, replacement of recombinant proteins, and transcript therapies in regenerative medicine. ethris GmbH has a strategic research collaboration with AstraZeneca and MedImmune, LLC. The company was founded in 2009 and is based in Planegg, Germany.
Cellular Biomedicine Group (CBMG)
Series A in 2021
Cellular Biomedicine Group (OTCQB: CBMG) is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development is the result of collaboration among scientists and doctors from the US, England and China.
Guangdong BeiKang Pharmaceutical Company Ltd
Acquisition in 2011
Guangdong BeiKang Pharmaceutical Company Ltd manufactures drugs which includes generic injectable antibiotics.
Whittier Street Health Center
Grant in 2014
Whittier Street Health Center (WSHC) is a comprehensive, innovative and high quality health care and wellness center championing equitable access to high quality, cost-effective health care for diverse populations. WSHC is accredited by The Joint Commission (TJC), certified by the NCQA as a golden level (highest ranking) patient centered medical home and licensed by the Massachusetts Department of Public Health (DPH). The vision of the Whittier Street Health Center is to serve as the premiere health center for Boston residents and the mission is to provide high quality, reliable and accessible primary care and support services to promote wellness and eliminate health and social disparities.
Located in the Roxbury neighborhood of Boston, Whittier Street Health Center provides comprehensive health services including primary care, behavioral health care, substance abuse services, dental care and eye care to over 25,000 patients.
A trusted member of the community for 80 years, Whittier is here to provide the care that you and your family need to get healthy and stay healthy.
We provide many services to help raise it out of poverty and into a place of good health. Having translators for 17 languages and utilizing clinical and social services to meet specific community needs through outreach, targeted programs and state of the art health care delivery helps us stay connected with the community.
ADC Therapeutics SA
Series E in 2017
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Moderna Therapeutics
Series E in 2015
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells.
Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.
Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
KuDOS Pharmaceuticals Ltd
Acquisition in 2005
KuDOS Pharmaceuticals Ltd discovers and develops drugs based upon the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
Manna Ministries
Grant in 2014
Manna Ministries has a longstanding commitment to fiscal responsibility and is audited each year by an independent CPA firm. Our audits reveal that 96% of our funding goes directly to support our programs, while only 4% goes to administrative costs. Partnerships allows us to help more people lead healthier lives by providing them with the basic necessities of life such as food, shelter, and healthcare.
Christiana Care Health Systems
Grant in 2014
Based in Wilmington, DE, Christiana Care Health System is one of the largest health care providers in the mid-Atlantic region, serving all of Delaware and parts of Pennsylvania, Maryland and New Jersey. We are a not-for-profit teaching health system that includes two hospitals with more than 1,100 patient beds, a home health care service, preventive medicine, rehabilitation services, a network of primary care physicians and an extensive range of outpatient services. Christiana Care is recognized as a regional center for excellence in cardiology, cancer, orthopaedics and women's health services, as well as for its Level-I trauma care and Level-3 neonatal intensive care (both highest capability).
Nektar Therapeutics
Post in 2013
Nektar Therapeutics is a biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Rani Therapeutics, LLC
Series D in 2017
Rani Therapeutics develops an oral biotherapeutics technology for the oral delivery of large drug molecules, including peptides, proteins, and antibodies.
The company was founded in 2012 and is based in San Jose, California.
Pearl Therapeutics
Acquisition in 2013
Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease.
Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.
Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.
Axbio
Series B in 2022
Axbio Inc. develops and manufactures technology for genetic sequencing. It offers products, such as stool genome extraction kit, blood genome extraction kit, saliva genome extraction kit, and bacterial genome extraction kit. The company provides sequencing and diagnostic systems, disposable biochips, and reagents. Axbio Inc. was founded in 2016 and is based in Shenzhen, China.
PhaseBio Pharmaceuticals
Series D in 2018
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
OnDosis
Seed Round in 2020
OnDosis AB develops and manufactures handheld dosing device. The company's product connects and enables patients to digital health services, including, treatment. The company was founded in 2017 and is headquartered in Gothenburg, Sweden.
ADC Therapeutics SA
Series D in 2016
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Our ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first- generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
UCHealth
Grant in 2014
UCHealth is a locally owned, private, not-for profit organization with a strong vision: to provide world-class health care.
UCHealth, based in northern Colorado since 1925, provides evidence-based health care and wellness services and products in Colorado, Nebraska and Wyoming. PVHS' service area covers more than 50,000 square miles.
UCHealthis a regional medical hub that includes Poudre Valley Hospital, Medical Center of the Rockies, Mountain Crest Behavioral Health Center, Poudre Valley Medical Group, and dozens of associated clinics and outpatient services.
The organization's mission is to be an integrated, independent, non-profit organization providing innovative, comprehensive care of the highest quality while exceeding expectations of the communities we serve.
Catherine’s Health Center
Grant in 2014
Established in 1996, Catherine’s Health Center is a 501(c)(3) safety net medical clinic, serving more than 6,000 patients annually. Using a small core of paid staff and many dedicated volunteers, Catherine’s mission is to provide free or low-cost medical services to low-income, uninsured and underinsured residents of Kent Count.Catherine’s Health Center is a non-profit community-based health facility dedicated to serving low-income, uninsured residents of the northeast sections of Grand Rapids, Michigan, primarily those who live in the Creston and Belknap neighborhoods. Supporting the center’s activities are a governing board and group of volunteers working to make health care available to those in need.
Rani Therapeutics, LLC
Venture Round in 2018
Rani Therapeutics develops an oral biotherapeutics technology for the oral delivery of large drug molecules, including peptides, proteins, and antibodies.
The company was founded in 2012 and is based in San Jose, California.
The Food Trust
Grant in 2014
The Food Trust, a nonprofit founded in 1992, strives to make healthy food available to all. Working with neighborhoods, schools, grocers, farmers and policymakers, we've developed a comprehensive approach that combines nutrition education and greater availability of affordable, healthy food.
FibroGen, Inc.
Post in 2016
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).
North Georgia Healthcare Center
Grant in 2014
North Georgia Healthcare Center is a non-profit health care center in Ringgold, Georgia. NGHCC is federally funded by the U.S.D.A. Direct Loan Program funds. The organization will seek sponsorship through private corporations, community, and grants and it will accept Private Insurance, Medicare, Medicaid. NGHCC will offer medical services to North Georgia and surrounding areas seven days a week with extended hours.
Sankofa Community Development Corporation
Grant in 2014
Sankofa Community Development Corporation, founded in 2008, serves as a catalyst to revitalize New Orleans’ Lower and Upper Ninth Ward communities. The nonprofit organization was established to facilitate advances in urban revitalization, healthy living, youth empowerment through education and intergenerational learning. Currently, Sankofa Community Development Corporation leads the Sankofa Mobile Market, Sankofa HEAL Project and Sankofa Learning Gardens and Farms Project.
ELVPHD
Grant in 2014
Elkhorn Logan Valley Public Health Department was created in 2002 to serve the citizens and communities of Burt, Cuming, Madison and Stanton counties. Located in Wisner, Nebraska, with a satellite office in Norfolk, the department focuses on healthy lifestyle management and disease prevention with over 20 programs initiated to maximize wellness and safety.
UnityPoint Health
Grant in 2014
Full Investment Portfolio:
Cash equivalents: 0.25%
U.S. Treasury obligations: 0.26%
U.S. government agency obligations: 0.06%
Municipal bonds: 0.04%
Asset Backed Securities: 0.45%
Mortgage-backed securities: 0.27%
Corporate bonds: 0.60%
Equity securities: 0.73%
Domestic Equity Securities PIF: 0.01%
Mutual funds: 72.42%
Alternative investments: 7.13%
Hedge Funds: 7.64%
Private equity funds: 3.99%
Fund of Funds: 5.40%
Interest rate swap agreements: 0.06%
Other items: 0.68%
Founded in 1993, UnityPoint Health is a non-profit organisation based in the United States. The foundation is a network of hospitals, clinics and home care services.
Takeda Respiratory Business
Acquisition in 2016
Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.
Moderna Therapeutics
Series F in 2016
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells.
Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.
Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
Mallory Community Health Center
Grant in 2014
Dr. Arenia C. Mallory Community Health Center (MCHC) is named to honor the memory of Dr. Arenia C. Mallory, well known educator and champion of human causes. She inspired young minds regardless of their race, economic or social status to “Walk in Dignity, Talk in Dignity, and Live in Dignity”.
Alexion Pharmaceuticals
Acquisition in 2020
Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.
Novexel
Acquisition in 2009
Novexel is a pharmaceutical company that researches and develops novel class antiinfectives for the treatment of severe and difficult to treat bacterial and fungal infections. The Company has an extensive portfolio of antibacterial and anti-fungal compounds, R&D programs, and intellectual property. Novexel’s focus is on novel antimicrobial compounds with activity against multi-resistantorganisms. Novexel’s expertise in Biology, Medicinal Chemistry, Pharmacology, Microbiology and Clinical Development positions the Company at the forefront of the discovery and development of novel therapies for infectious disease.
Cambridge Antibody Technology
Acquisition in 2006
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England.
Innate Pharma
Corporate Round in 2018
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.
The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.
Arrow Therapeutics
Acquisition in 2007
Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery.
Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.
